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Abstract 
Clinicians who manage delirium must do so without key information required for evidence-based 
practice, not least lack of any clearly effective treatment for established delirium. Both the nature of 
delirium, and the methods used to research it, contribute to difficulties. Delirium is heterogeneous, 
with respect to motor subtype, aetiology, setting and the co-existence of dementia, and may be 
almost inevitable towards the end of life. Elements of assessment are subjective, so diagnosis can be 
uncertain or unreliable. Defining objectives of care and outcomes is sometimes unclear. Better 
identification and case definition, including seeking biomarkers, stratification by type, or aetiology, 
and application of more complex models of causation may help. This will likely require further 
observational epidemiology, imaging, and laboratory-based research before further rounds of large-
scale randomised controlled trials. Application of trial methodologies designed for drug treatments 
of better-defined conditions may have failed to take account of the complexities both of diagnosis 
and complex intervention in delirium. Both drug and complex intervention trials need sufficient 
preliminary work to ensure that the right dose, duration or intensity of treatment is delivered and a 
ƌĂŶŐĞŽĨ ‘ŝŶƚĞƌŵĞĚŝĂƚĞ ?ĂŶĚ ‘ƉƌŽǆŝŵĂů ‘ŽƵƚĐŽŵĞŵĞĂƐƵƌĞƐĂƐƐĞƐƐĞĚ. Re-purposing of established 
drugs may provide a source of investigational products. Greater use of alternative research 
methodologies (qualitative, realist), or adjuvants to trials (process evaluation) will help answer 
questions about focus, generalisability and why interventions succeed or fail. Delirium research will 
have to embrace both Ă ‘ďĂĐŬƚŽďĂƐŝĐƐ ?ĂƉƉƌŽĂĐŚǁŝƚŚŝŶĐƌĞĂƐĞĚďƌĞĂĚƚŚŽĨŵĞƚŚŽĚŽůŽŐŝĞƐƚŽŵĂŬĞ
progress. 
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WHERE NEXT FOR DELIRIUM RESEARCH? 
Research is generalizable new knowledge. Clinical practice is best served when informed by rigorous 
evidence. This includes definition, identification, risk factors and causes, aetio-pathogenesis, 
prevention, drug and non-drug treatment, consequences, natural history and prognosis. Systematic 
knowledge allows correct diagnosis, investigation, intervention and information-giving, and the 
avoidance of myth, presumption, and what does not work. This paper describes some of the gaps in 
our knowledge of delirium, and the challenges in undertaking clinical research and translating 
findings into practice. 
Is there a problem? 
Delirium research funding and effort is relatively small compared with the size of the clinical 
problem. Recent decades have seen undoubted progress in knowledge about delirium (Inouye et al 
2014), but research has not yet answered many important questions to which clinicians, patients 
and families require answers. 
Prevention of delirium represents the ideal, but, at best, a third of incident hospital delirium can be 
prevented, and prevalent delirium is an equal or greater problem. Clinical recognition of delirium 
remains poor (Saczynski et al 2014, Kales  et al 2003, Bellelli et al 2015). Brief screening tools help 
(Inouye 2003, Bellelli et al 2014), but depend on adequate training of staff who use them, and are 
inconsistently applied. On their own they are of insufficient validity to make a definite diagnosis, 
despite a tendency to interpret them as diagnostic.   
Where delirium is detected, optimal strategies for management, symptom control and longer-term 
follow-up are unclear. Prospective studies have identified poorer cognitive, functional and survival 
outcomes in individuals following an episode of delirium (Witlox et al 2010, Siddiqi et al 2006, Fick et 
al 2013). However, the degree to which increased risk results from the neurochemical disturbance of 
delirium per se, the severity of the physiological insult, decompensation in individuals with an 
underlying tendency to adverse outcomes (confounding by frailty), complications, poor care, or a 
combination of all these factors is unknown (Teale and Young 2015).  
Predictive factors for recovery of delirium, including different symptom patterns and in different 
clinical contexts are poorly understood, although hypoactive delirium has a poorer prognosis 
(Jackson et al 2016b).  
Further progress requires us to understand why research is difficult, in order to avoid unjustified 
assumptions and to allow more appropriate study design. Methodologically-based disciplines can 
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help. For example, epidemiology is the study of the occurrence and causes of disease in populations, 
exploiting the paradox that the best information about individuals can come from the study of 
variation in characteristics between groups (Hennekens et al 1987). Heterogeneity in delirium 
presentation, and the patients it affects, offers a research opportunity. Epidemiological studies are 
not the only approach or research need, however. In order to advance knowledge we need to 
convert plausible laboratory, physiological, biochemical and pharmacological principles and 
hypotheses into practical interventions. Linking these methodologies with clinical research forms the 
 ‘first translation gap ?. A further challenge is implementation  ?ƚŚĞ ‘ƐĞĐŽŶĚƚƌĂŶƐůĂƚŝŽŶŐĂƉ ? ?, the 
discipline of promoting and evaluating research knowledge in clinical practice  (Oborn et al 2010).   
Definition and diagnosis  
Disease taxonomy has a long history and has evolved with advances in imaging, cell biology, 
immunology and genetics. Inferring pathologies from clinical manifestations or syndromes (groups of 
signs and symptoms) is the basis of clinical medicine (Cassell 2004). Where this is possible, it can lead 
to specific treatment, with the aim of eradicating the disease (cure). This model is inadequate for 
many modern health problems, in particular chronic and degenerative diseases, multi-morbidity and 
mental ill-health.  
Most mental health diagnoses are syndromes with uncertain or unknown underlying pathology.  The 
process of diagnosis requires an additional search for underlying pathologies and predisposing 
factors (Zachar and Kendler 2007). The Virchow notion of a single causal factor (originally applied to 
infectious diseases) is inadequate.  A more likely mechanism for syndromes is one of predisposition 
and precipitant (Laurila et al 2008). These may change with time (for example, changing patterns of 
drug prescription) and demographic (ageing being associated with loss of cognitive reserve or 
dementia). Up to two-thirds of cases of delirium have more than one causal factor, and in up to 20% 
no cause can be found for clinically convincing delirium, despite full investigation (Laurila et al 2008, 
Rudberg et al 1997, George et al 1997).  
,ŽŵŽŐĞŶĞŝƚǇŝŶƚŚĞ ‘ŽƵƚĐŽŵĞǀĂƌŝĂďůĞ ?ŽĨĂŶĞƉŝĚĞŵŝŽůŽŐŝĐĂůŽƌĐůŝŶŝĐĂůŝŶǀĞƐƚŝŐĂƚŝŽŶŝƐĨƵŶĚĂŵĞŶƚĂů ?
If the study is not (mostly) of a single condition, the ability to identify associated, or potentially-
causal, factors is reduced. Delirium is a clinical diagnosis, but diagnosis is difficult. Mimics include 
dementia with Lewy bodies, progression of vascular dementia, the impact of a disorientating, 
overstimulating and overwhelming environment (for example, hospitalisation) in someone with 
dementia or intellectual disability, sleep deprivation, or pain (Sampson et al 2014).   
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The cardinal feature of delirium is impaired attention, but there is a danger that the two are seen as 
synonymous. In order for attention to be assessed, there must be sufficient arousal (the patient 
must be alert enough to be assessed). In the absence of another cause of reduced conscious level, 
patients too drowsy to be assessed should be classified as having inattention (European Delirium 
Association 2014). Whilst important for test sensitivity, this reduces specificity, resulting in  ‘false 
positiveƐ ?. Testing attention invariably tests other cognitive or sensory modalities (memory, 
calculation, language, vision), which can cause problems; for example, many people with dementia 
cannot recite the months of the year backwards, a commonly-used clinical test for attention. Other 
features of the delirium syndrome are also important (onset or change, fluctuation, cognitive 
impairment, motor restlessness or retardation, psychosis, emotional control or lability, autonomic 
dysfunction), but many of these are also difficult to detect. Aphasia can make assessment of 
memory, attention or logical thought impossible. Barriers to valid and reliable detection of delirium 
include the training required to identify clinical signs, or administer diagnostic tests, the fluctuating 
nature of delirium, and the possibly subjectivity in assessment.  
Diagnostic research has concentrated on identification of diagnostic algorithms or tests, and 
ǀĂůŝĚĂƚŝŶŐƚŚĞƐĞĂŐĂŝŶƐƚƚŚĞ ‘ŐŽůĚƐƚĂŶĚĂƌĚ ?ŽĨĐůŝŶŝĐĂůƌĞƐ ĂƌĐŚĚŝĂŐŶŽƐƚŝĐĐƌŝƚĞƌŝĂ ?ĚĂŵŝƐĞƚĂů
2010). This is necessary and useful, but unless both sensitivity and specificity are very high, study of 
incidence and prevalence will be incorrect. Poor validity in case definition or outcomes 
measurement prevents meaningful research. Research into biomarkers for delirium has been limited 
and no objective delirium test with acceptable diagnostic accuracy has been identified. 
In delirium research, this has several important implications:  
1. Definition is to some extent arbitrary (witness changing Diagnostic and Statistical Manual 
diagnostic criteria over the years) (Sepulveda 2015) 
2. Diagnostic criteria assembled for the purposes of taxonomy or research must be 
operationalised for clinical use 
3. ŽŶĐĞƉƚƵĂůŝƐŝŶŐĚĞůŝƌŝƵŵĂƐĂ ‘ĚŝƐĞĂƐĞ ?ŵĂǇbe misleading 
4. The validity of a clinical diagnosis is not necessarily secure.  
Heterogeneity in delirium, and those who develop it 
Delirium is currently held to represent a single condition, but is varied in its presentation and 
features, and may represent a number of different conditions, based on:  
1. Motor subtype (hyper- vs hypo-active) 
5 
 
2. Aetiology (neurological infections, neurological injury or disease, systemic infections, 
anticholinergic drugs, other drugs, drug or alcohol withdrawal, electrolyte disturbance, renal or liver 
failure, hypoxia, vascular disease).  
3. Setting (surgical vs medical vs intensive care units vs palliative care) 
4. The presence or absence of prior dementia. 
The argument for these being a single condition is fulfilment of diagnostic criteria for the syndrome. 
The argument against is the possibility of different causal mechanisms (and lack of evidence of a 
single common final pathway), and different natural history and prognosis. The solution is to study 
these groups separately, which requires large numbers of study participants and most likely, multi-
centred research. Imaging or biochemical clinical aetiological research may help, if biomarkers for 
different sub-types or strata can be identified. 
Particular evidence for heterogeneity in the delirium syndrome relates to recovery. Delirium is 
typically described as reversible cognitive impairment, but is also associated with high mortality 
(Siddiqi et al 2006). In published series, 40% of delirium has resolved within 24h, but 30% persists 
more than a month and 21% more than 6 months (Cole et al 2009).  
A major emerging hypothesis is that episodes of delirium cause permanent cognitive damage, and 
this represents a mechanism through which dementia deteriorates (Davis et al 2012, Fong et al 
2015). An alternative hypothesis is that delirium is a manifestation of frailty resulting from poor 
reserve to maintain homeostasis, disproportionate physiological impact of relatively minor insults, 
and risk of incomplete recovery following decompensation (Teale and Young 2015). This is supported 
in some series where survival, cognitive and functional recovery have all been poor (Whittamore et 
al 2014). Cognitive failure may, in medical/geriatric and palliative care settings,  be a function of 
frailty and multi-system failure in those approaching the end of life ?ĂŶĚƚŚĞƌĞĨŽƌĞŶŽƚ ‘ƚƌĞĂƚĂďůĞ ?Žƌ
reversible.  
Most delirium occurs on a background of prior dementia and this poses particular problems (Fick et 
al 2013, Fick et al 2002, Mukadem and Sampson 2011, Morandi et al 2017). Many of those admitted 
with delirium without a prior dementia diagnosis will either have undiagnosed dementia, or their 
families describe clear if subtle signs of prior cognitive problems not reaching the diagnostic 
threshold, indicating  ‘frail brains ? (Jackson et al 2016a). It can be argued that in the context of acute 
physical illness and the hospital setting it is impossible to distinguish delirium, dementia and 
delirium superimposed on dementia. For example in hospital, sleep is often disturbed due to the 
effects of illness, day time inactivity, environmental noise, or dementia itself. Many older people 
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 ‘ŶĂƉ ?ĚƵƌŝŶŐƚŚĞĂĨƚĞƌŶŽŽŶ ?dŚŽƐĞǁŚŽƐůĞĞƉƉŽŽƌůǇat night may do so in the day, or become 
irritable and unable to sustain focus on mentally taxing tasks. Does this represent delirium or merely 
sleep deprivation? Is sleep deprivation a cause of delirium or does it just cause similar symptoms? 
^ŝŵŝůĂƌĂƌŐƵŵĞŶƚƐŚŽůĚĨŽƌƉĂŝŶĂŶĚĐŽŶƐƚŝƉĂƚŝŽŶ ? ‘ŽŐŶŝƚŝǀĞƐƉĞĐƚƌƵŵĚŝƐŽƌĚĞƌƐ ? Wdefining a range 
of cognitive conditions in acute hospitals, including delirium, delirium superimposed on dementia 
and dementia, has been proposed as an alternative, with the final diagnosis to be determined at 
follow-up (Reynish 2015). This is not to deny the existence of delirium, but to acknowledge our 
inability to identify it as an entity in some situations, whilst acknowledging the similar needs of other 
groups (such as people with dementia or intellectual disabilities) when in a crisis which may have 
medical, mental health or social origins. 
Objectives of care 
Healthcare need is the potential to benefit from an assessment or therapeutic intervention. Benefit 
is often stated ŝŶƚĞƌŵƐŽĨ ‘ŚĞĂůƚŚŐĂŝŶ ?, a change in measureable health status, such as disease 
presence, function or quality of life, but could include prevention, palliation, information-giving or 
reassurance, or family and carer support. If delirium is an unavoidable part of dying, or a non-specific 
driver of crises in people with dementia or frailty, then the goals of treatment should focus primarily 
on relieving distress and optimising function, in contrast to those in whom delirium is an unpleasant 
epiphenomenon arising in the course of a primary medical disorder, where the goal is cure or 
disease control. There has been virtually no research on symptom control in delirium, as an outcome 
per se (Partridge et al 2013).  
Instead, research has focused on delirium occurrence or resolution. This has advantages, especially 
for research efficiency (the outcome reflects the condition of primary interest), but there are 
limitations. If the assessment is at least in part subjective, an opportunity for ascertainment bias is 
introduced. This is of particular concern in trials of complex interventions where blinding is difficult, 
and may result in a tendency to overstate the size of treatment effects. More objective  outcomes 
(death or care home placement) Žƌ ‘ĚŝƐƚĂůŽƵƚĐŽŵĞƐ ?(disability or quality of life) can be measured to 
avoid bias, but may be relatively infrequent, compromising statistical power, or subject to multiple 
causes or influences (such as co-morbidity, or socio-economic circumstances), making treatment 
effects specific to delirium harder to discern (Teale and Young 2015). 
As well as pathologies, problems can be defined at the level of organs or anatomical parts 
(impairments, such as pain, poor visual acuity, attention, memory loss or delusions), tasks or 
capabilities (walking, reading, social behaviour), activity or participation (successful function in a 
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physical and social environment, taking account of contextual factors) (World Health Organization 
2001). This opens the possibility of intervention at the palliative, functional, social and 
environmental level. To date these approaches have been little studied. 
Avoidance of complications or unintentional harm is an important mechanism for health gain in 
older people, and the avoidance of healthcare associated harm is the focus of worldwide political 
action (Department of Health 2016). Interference with, or resistance to, necessary medical 
intervention, falls and fractures, pressure ulcers, deconditioning, malnutrition, distress, affront to 
identity and  depersonalisation,  and post-traumatic stress disorder are delirium-specific examples. 
These will not necessarily be captured by focus on delirium prevention or recovery, but are 
important patient-centred outcomes in their own right.   
Issues with the existing delirium evidence base 
Evidence-based practice requires valid evidence. Research evidence in delirium is incomplete, and 
varies in quality, so interpretation and appreciation of limitations is required. Lack of evidence of 
benefit is not the same as evidence of lack of benefit. Avoiding therapeutic nihilism requires us to 
work with uncertainty. 
Both prevention and treatment trials are hard to do, because of the complex packages of measures 
necessary, the time-frame for recruitment and intervention, and the pressures and competing 
priorities of emergency healthcare. Trials may be confined to efficacy trials in exemplar conditions 
(such as hip replacement) when logistics are more easily controlled, and delirium rates high. This 
raises questions of generalisability; it does not prove that evidence is not generalisable, but 
introduces uncertainty. Alternatively, non-randomised clinical studies may be undertaken (Slaets et 
al 1997, Inouye et al 1999, Holt et al 2013), which are pragmatic, and provide evidence, if carefully 
done and interpreted. However, they are prone to bias, uncertainty about causal relationships, and 
misleading conclusions.  
The absolute priority given to randomised controlled trials may need to be reconsidered. Because 
trials are difficult, they are often small (although there are many delirium trials with several 
hundreds of participants). Type 2 statistical error is falsely rejecting the null hypothesis because of 
insufficient statistical power  W trials too small to be sure that results were unlikely to have arisen by 
chance. Power depends on outcome event rates rather than size alone; there are several recent 
examples of good-sized but underpowered trials (Hempenius et al 2013, Jeffs et al 2013). Small size 
also limits the ability to explore variations by subgroups (treatment by subgroup interaction). A 
recent pragmatic multicentre cluster randomised controlled feasibility trial of a multicomponent 
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delirium prevention intervention concluded that a definitive trial in routine care would require 2300 
participants in each arm (Young et al 2015, Green et al 2016), which would be expensive and 
logistically challenging. Meta-analysis increases precision in effect size, but concerns remain about 
heterogeneity in interventions and publication bias (a tendency for negative trials not to be 
published) (Siddiqi et al 2016a, Hshieh et al 2015, Martinez et al  2012, Al-Quadheeb et al 2014, 
Gilmore and Wolfe 2013).  
Drug trials require a lot of preliminary work to ensure that they have the best chance of success, and 
this has not always been done in delirium, including lack of dose-ranging, determination of optimal 
duration of treatment or timing of outcome assessment.  
A trial measures a difference between two treatments, or an active treatment and none. Standard 
clinical trials recognise the problems of protocol violation and crossover, and to an extent simple 
drug trials can cope with this without losing interpretability (although size of treatment effect will be 
underestimated). The design of trials (randomisation, stratification or minimisation, permuted 
blocks, and sufficient size) to ensure baseline balance between groups, and analysis by intention-to-
treat, is designed to ensure that results are unbiased (results are unlikely to be due to any factor 
other than treatment). Control groups serve to eliminate the effects of time, natural history, 
comorbidity, intercurrent illness, attention and measurement. Ideally a placebo or sham control is 
used, which is feasible in drug trials, but less so for complex interventions. It is often impossible to 
ŚĂǀĞĂƚƌƵůǇ ‘ŝŶĂĐƚŝǀĞ ?ŽƌƵŶƚƌĞĂƚĞĚĐŽŶƚƌŽůŐƌŽƵƉ ?Ɛo interpreting treatment effect sizes becomes 
difficult: Ă ‘ŶĞŐĂƚŝǀĞ ?ƚƌŝĂůŵĂǇŵĞƌĞůǇŝŶĚŝĐĂƚĞdilution of the treatment effect, or that both 
treatment conditions were effective. 
A single main trial outcome is specified because of the possibility of chance associations when 
multiple outcomes are used, and the risk of exploitation by (commercial) vested interests when such 
associations are reported. However, these considerations are less relevant to complex interventions 
(Medical Research Council 2008, Goldberg et al 2013).  There are many dimensions of health 
experience, from disease-specific physiological or functional measures, through generic health 
status, quality of life and psychosocial variables such as experience and satisfaction. Defining what 
consƚŝƚƵƚĞƐĂ ‘ŐŽŽĚ ?ŽƵƚĐŽŵĞŝƐƉĂƌƚŝĐƵůĂƌůǇƚƌŽƵďůĞƐŽŵĞfor frail older people. If it is not possible to 
prevent or treat delirium, attenuation of symptoms (or reduction in the distress they cause) may be 
an appropriate outcome. However, measurement of these patient-focused outcomes is challenging, 
especially in individuals who may be unable to communicate how they are feeling (Goldberg and 
Harwood 2013).  
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Increasingly, trials are cluster randomised (at the level of a ward or hospital rather than the 
individual; for example, Siddiqi et al 2016b). This introduces additional problems with contamination 
and cluster effects, requiring inflated sample sizes.  
There are many practical difficulties in undertaking delirium research. Researchers may defer 
performing delirium assessments, or clinical staff may deter researchers from approaching patients 
at the point of determining trial eligibility if they are frail or unwell (when they are most at risk from 
delirium). Missing delirium assessments may occur when patients are unavailable or unwilling to 
undergo testing. The hierarchical nature of data obtained from repeated assessments, managing 
missing data, and determining delirium duration and severity from longitudinal data (especially 
where there is fluctuation) are challenges for data analysis.  
The evidence for benefit of delirium prevention interventions 
The preventative paradigm aims to influence behaviour at individual, organisational or societal 
levels. Delirium is more common amongst patients treated in some ways than others; delirium can 
be caused or prevented. Regional anaesthesia (for example, Williams-Russo 1995, Marino et al 
2009), use of dexmedetomidine sedation in intensive care units (Pasin et al 2013, Su et al 2016), 
proactive ortho-geriatric consultation (Marcantonio et al 2001, Lundström et al 2007), and post-
acute rehabilitation out of hospital (Siddiqi et al 2016a, Caplan et al 2006) all have credible 
supportive evidence for prevention from randomised controlled trials. There is evidence to support 
delirium prevention through multicomponent interventions: meta-analysis of randomised trials 
demonstrate an overall beneficial effect (Hshieh et al 2015, Martinez et al 2012), but the effect is 
diluted in routine care settings, and there is no consensus on the critical components of these 
interventions. Benefit may simply represent attention to basic care (mental stimulation, hydration, 
nutrition, correction of sensory impairment, mobility, sleep promotion) and avoidance of harmful 
practice. 
Much delirium does not appear to be preventable, and in some circumstances (e.g. advanced frailty, 
or at the end of life), delirium may be all but inevitable. For those with frailty, disproportionate 
physical and cognitive decompensation may occur in response to what may be considered to be a 
relatively minor insult and this, rather than the severity of the insult per se, is likely to contribute to 
poor outcomes. It may make more sense to investigate generic interventions in frailty (including 
targets such as falls, nutrition, immobility and incontinence) rather than delirium-specific 
interventions alone ?/ŶŵĂŶǇ ‘ŵĞĚŝĐĂů ?ĚŝƐĐŝƉůŝŶĞƐ ?ŝŶĐůƵĚŝŶŐintensive care and palliative care, there 
are multiple competing priorities, which may have conflicting impacts on outcomes, including the 
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occurrence of delirium. Analgesia is an example: painful diseases, pain itself and analgesic drugs may 
all cause delirium. There may be a trade-off between avoidance of deconditioning and immobility 
and the occurrence of in-patient falls. Delirium prevention will form part of a comprehensive 
package.  
The evidence for delirium treatment interventions 
The 1999 American Psychiatric Association guideline on delirium stated (amongst much good advice) 
ƚŚĂƚ ‘antipsychotic medications are the pharmacologic treatment of choice ? (American Psychiatric 
Association 1999). This advice was based largely on custom and practice. Since then, many trials 
have investigated single agent drug treatments, notably antipsychotics, pro-cholinergics and 
cholinesterase inhibitors, melatonin, and benzodiazepines (for example, Page et al 2013, de Jonghe 
et al 2014, van Eijk et al 2010). Some suggest a treatment effect, but none, nor any meta-analysis, 
provides evidence beyond reasonable doubt. Similarly complex interventions including geriatric 
assessment, delirium units and management advice and follow-up have also suggested treatment 
effects without any certainty (for example, Cole et al 1994, Cole et al 2002, Baldwin et al 2004, 
Pitkälä et al 2006, Goldberg et al 2013). Current guidance from the UK National Institute for Health 
and Clinical Excellence (NICE) acknowledges the paucity of evidence for treatment of delirium, and is 
unable to recommend the routine use of any pharmacological agent (National Institute for Health 
and Clinical Excellence 2010). Overall it is fair to say that no treatment intervention has convincing 
evidence of efficacy or effectiveness. 
Solutions  
The first requirement is for basic clinical, imaging, biomarker and epidemiological research 
systematically to investigate how delirium might subdivide, or (as current thinking holds) represent a 
single entity. This will require funders to support work one step removed from clinical trials and their 
immediate impact on clinical practice. More accurate information on phenomenology, prevalence, 
incidence, associations, risk factors, and natural history is required on a scale not previously 
attempted, including for subgroups (e.g. those with dementia and frailty) and subtypes (e.g. hyper- 
vs hypoactive delirium, or by cause). 
Current pharmacological interventions are based on limited trial evidence of efficacy and have 
potentially serious side-effects, especially in older people with co-existing dementia. Further drug 
trials are urgently required based on new and plausible theories of patho-aetiology of delirium to 
identify potentially novel therapeutic targets, grounded in sound scientific principles. Repurposing of 
drugs with an existing license and safety record could form the basis of this work. Early phase 2 trials 
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are required with momentum maintained to bridge the first translational gap for drugs that show 
promise. Joined-up working between laboratory and clinical researchers would help to identify 
targets for future drug trials. 
A broader view on outcomes is required. In the absence of an objective measure of delirium, 
reduction in incident delirium and delirium severity are difficult to measure. In some settings (e.g. 
advanced frailty or palliative care) relief of suffering or distress and maintenance of function is as 
important as resolution of delirium and restoration of cognition (Cassell 2004).  
An area rarely considered in medical research is that of epistemology. The dominant philosophy is 
positivist  W ǁŚŝĐŚŚŽůĚƐƚŚĂƚǇŽƵƐŚŽƵůĚŶŽƚďĞůŝĞǀĞǁŚĂƚŚĂƐŶ ?ƚďĞĞŶƉƌŽǀĞĚ ?ŚĞŶĐĞƚŚĞŝŵƉŽƌƚĂŶĐĞ
of randomised controlled trials, and the approaches used in health technology assessment and 
prioritisation bodies such as the National Institute for Health and Care Excellence (NICE). This poses 
an inherent risk. McNamara ?s fallacy holds that what cannot be measured is not important, or 
worse, does not exist (Wikipedia 2016). Strictly a randomised controlled trial answers a single 
question (about drug dose, or configuration of complex services, in a defined group at baseline, on a 
particular outcome measure). Ensuring these are optimised is important but difficult, and may 
require a series of trials investigating different subgroups or treatment or outcome variation. Trials 
are expensive, time-consuming and labour-intensive, making this an ambitious goal. Funders and 
researchers soon lose interest, often after only a single large trial has been completed.  
Realist evaluation investigates what works, for whom, under what circumstances, and why (Wong 
2015). /ƚĚŽĞƐƚŚŝƐďǇƉƌŽƉŽƐŝŶŐ ‘ŵŝĚĚůĞƌĂŶŐĞƚŚĞŽƌŝĞƐ ? ?ŽƌďƌŽĂĚpropositions defining context, 
mechanism and outcome, and how they relate. This widens and enhances the study of applicability 
and generalisability, but in doing so demands we accept different, and less rigorous, quality of 
evidence. Realism considers, and appraises, any available evidence that might contribute support or 
contradict a theory. The focus of uncertainty is shifted from doubts about effect size and 
generalisability inherent in trials methodology, to questions of validity and causality inherent in 
other research designs. However, trials remain an important source of evidence. Embedding 
subgroup and process evaluation in trials contributes valuably to realist evaluation. Process 
evaluation asks why trials may not have shown an anticipated effect through examination of 
treatment-related problems (fidelity), research-related issues, mechanisms and contextual factors 
(facilitators, barriers) that provide, explain and determine the necessary conditions for a treatment 
to be effective (Moore et al 2014). Given the variations around delirium research this is particularly 
important, but to date little done. 
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Qualitative methodologies may contribute. Examples include studying the experience and meaning 
of delirium for patients, carers and staff (for example, Partridge et al 2013, Morandi et al 2015). This 
in turn, can define treatment goals and patient-centred outcome measures. For staff, understanding 
interaction with hospital processes, and competing priorities such as throughput and risk, is needed 
if delirium prevention and treatment programmes are to be successfully implemented. The 
importance of patient and public participation in all aspects of research has been highlighted in the 
UK over the past decade in terms of generation of research questions, research delivery, 
interpretation and impact. The development of outcomes focused on reducing the distressing 
symptoms of delirium would be well-informed by involving individuals who have experienced 
delirium.  
Conclusion 
Despite encouraging progress, delirium research has failed to have sufficient impact on clinical 
practice. The use of limited and limiting research paradigms  W often for justified reasons  W has 
contributed. In the policy arena it has served to explain delirium as  ‘a disease ? that can be prevented, 
or relatively easily identified and treated, with the presumption that successful treatment of the 
underlying cause will be followed by cognitive and clinical recovery. This has been influential in 
guideline development and recommendations for clinical practice. However, there is little existing or 
emerging evidence to support this paradigm. 
Instead we have a syndrome, which shows considerable heterogeneity, and may not be a single 
condition, bearing a complex relationship with dementia and other causes of physical and 
neurological frailty. Identification is difficult, and in some settings may be impossible, at least with 
any degree of certainty. Single causes are the exception not the rule, and a model of predisposition 
and precipitant may serve better. Reversibility is uncertain and in general, survival, cognitive and 
functional outcomes are poor for some subgroups at least. The possibility that a simpler disease 
model may be valid for some groups (for example, post-operatively) remains enticing, and should 
not be abandoned entirely.    
Observational research on aetiology and causal factors is incomplete. The dominance of randomised 
controlled trials in understanding treatment effects has been unproductive, partly because too little 
preparatory work has been done before embarking on trials, and secondly because process 
evaluations have not been used to explain why the results occurred. Fundamental re-evaluation of 
the approach to delirium research may reveal findings that will drive a necessary step-change in 
clinical practice.  
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Key points 
x Convincing evidence indicated that some delirium can be prevented, but little evidence for 
effective treatment of established delirium 
x Delirium is a heterogeneous syndrome, that can be difficult to diagnose with certainty, 
which needs to be taken into account in delirium research 
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x Research has focussed on narrow views of causation and objectives of care, which should be 
broadened in future 
x Research is restricted by a concentration on randomised controlled trials; other research 
methodologies should be explored in addition. 
